Literature DB >> 17846812

Switching from methylphenidate immediate release to MPH-SODAS in attention-deficit/hyperactivity disorder.

Carlos Renato Moreira Maia1, Breno Córdova Matte, Henrique Tschoepke Ludwig, Luis Augusto Rohde.   

Abstract

OBJECTIVE: To assess ADHD symptoms after switching from Methylphenidate Immediate-release (MPH-IR) to Methylphenidate Spheroidal Oral Drug Absorption System (MPH-SODAS) in clinically stable patients with ADHD and to identify predictors of dissatisfaction with MPH-SODAS.
METHODS: This is an 8-week open clinical trial. Patients were assigned to MPH-SODAS according to their pre-study dose of MPH-IR. Assessments at baseline were conducted using the Swanson, Nolan, and Pelham-IV Questionnaire (SNAP-IV), and the Barkley's Side Effect Rating Scale (SERS). Potentials predictors of treatment response were evaluated.
RESULTS: From 62 patients, 47 completed the protocol. There was no significant change in the total score at the SNAP-IV (F (1,51.26) = 0.01; P = 0.91) and its subscales scores during the trial. Although no significant effect on the SERS total score (F (1,111.49) = 0.75; P = 0.39) was found, one adult patient with a previous cardiovascular condition presented a hemorrhagic cerebral vascular accident resulting in her obit. Overall, 46 (74.2%) patients reported to be satisfied. No factor assessed predicted dissatisfaction in univariated analyses.
CONCLUSION: Results suggested that switching from MPH-IR to MPH-SODAS did not affect stabilization of ADHD symptoms in the majority of patients. MPH prescription in patients with previous cardiovascular conditions must be extremely careful. Further studies with long-acting MPH including larger samples and patients not responsive to MPH-IR are needed especially in countries outside the US.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17846812     DOI: 10.1007/s00787-007-0647-7

Source DB:  PubMed          Journal:  Eur Child Adolesc Psychiatry        ISSN: 1018-8827            Impact factor:   4.785


  46 in total

Review 1.  Move over ANOVA: progress in analyzing repeated-measures data and its reflection in papers published in the Archives of General Psychiatry.

Authors:  Ralitza Gueorguieva; John H Krystal
Journal:  Arch Gen Psychiatry       Date:  2004-03

Review 2.  Pharmacological management of treatment-induced insomnia in ADHD.

Authors:  Christopher J Kratochvil; Marybeth Lake; Steven R Pliszka; John T Walkup
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2005-05       Impact factor: 8.829

3.  Side effects of methylphenidate in children with attention deficit hyperactivity disorder: a systemic, placebo-controlled evaluation.

Authors:  R A Barkley; M B McMurray; C S Edelbrock; K Robbins
Journal:  Pediatrics       Date:  1990-08       Impact factor: 7.124

Review 4.  Predicting the response of hyperkinetic children to stimulant drugs: a review.

Authors:  R A Barkley
Journal:  J Abnorm Child Psychol       Date:  1976

5.  Clinical relevance of the primary findings of the MTA: success rates based on severity of ADHD and ODD symptoms at the end of treatment.

Authors:  J M Swanson; H C Kraemer; S P Hinshaw; L E Arnold; C K Conners; H B Abikoff; W Clevenger; M Davies; G R Elliott; L L Greenhill; L Hechtman; B Hoza; P S Jensen; J S March; J H Newcorn; E B Owens; W E Pelham; E Schiller; J B Severe; S Simpson; B Vitiello; K Wells; T Wigal; M Wu
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2001-02       Impact factor: 8.829

6.  An open-label, randomized, active-controlled equivalent trial of osmotic release oral system methylphenidate in children with attention-deficit/hyperactivity disorder in Taiwan.

Authors:  Susan Shur-Fen Gau; Hsin-Yi Shen; Wei-Tusen Soong; Churn-Shiouh Gau
Journal:  J Child Adolesc Psychopharmacol       Date:  2006-08       Impact factor: 2.576

7.  Interrater agreement for the schedule for affective disorders and schizophrenia epidemiological version for school-age children (K-SADS-E).

Authors:  Guilherme V Polanczyk; Mariana Eizirik; Victor Aranovich; Daniel Denardin; Tatiana L da Silva; Tatiana V da Conceição; Thiago G Pianca; Luis Augusto Rohde
Journal:  Braz J Psychiatry       Date:  2003-06       Impact factor: 2.697

8.  Efficacy and safety of Ritalin LA, a new, once daily, extended-release dosage form of methylphenidate, in children with attention deficit hyperactivity disorder.

Authors:  Joseph Biederman; Declan Quinn; Margaret Weiss; Sabri Markabi; Meredith Weidenman; Kathryn Edson; Goeril Karlsson; Harald Pohlmann; Sharon Wigal
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

9.  Which boys respond to stimulant medication? A controlled trial of methylphenidate in boys with disruptive behaviour.

Authors:  E Taylor; R Schachar; G Thorley; H M Wieselberg; B Everitt; M Rutter
Journal:  Psychol Med       Date:  1987-02       Impact factor: 7.723

10.  Which treatment for whom for ADHD? Moderators of treatment response in the MTA.

Authors:  Elizabeth B Owens; Stephen P Hinshaw; Helen C Kraemer; L Eugene Arnold; Howard B Abikoff; Dennis P Cantwell; C Keith Conners; Glen Elliott; Laurence L Greenhill; Lily Hechtman; Betsy Hoza; Peter S Jensen; John S March; Jeffrey H Newcorn; William E Pelham; Joanne B Severe; James M Swanson; Benedetto Vitiello; Karen C Wells; Timothy Wigal
Journal:  J Consult Clin Psychol       Date:  2003-06
View more
  4 in total

1.  Treatments for Adolescents With Comorbid ADHD and Substance Use Disorder: A Systematic Review.

Authors:  Michelle J Zaso; Aesoon Park; Kevin M Antshel
Journal:  J Atten Disord       Date:  2015-02-05       Impact factor: 3.256

2.  Editorial: Observational studies in ADHD: the effects of switching to modified-release methylphenidate preparations on clinical outcomes and adherence.

Authors:  Aribert Rothenberger; Manfred Döpfner
Journal:  Eur Child Adolesc Psychiatry       Date:  2011-10       Impact factor: 4.785

3.  The occurrence of adverse drug reactions reported for attention deficit hyperactivity disorder (ADHD) medications in the pediatric population: a qualitative review of empirical studies.

Authors:  Lise Aagaard; Ebba Holme Hansen
Journal:  Neuropsychiatr Dis Treat       Date:  2011-12-16       Impact factor: 2.570

Review 4.  Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of adverse events in non-randomised studies.

Authors:  Ole Jakob Storebø; Nadia Pedersen; Erica Ramstad; Maja Lærke Kielsholm; Signe Sofie Nielsen; Helle B Krogh; Carlos R Moreira-Maia; Frederik L Magnusson; Mathilde Holmskov; Trine Gerner; Maria Skoog; Susanne Rosendal; Camilla Groth; Donna Gillies; Kirsten Buch Rasmussen; Dorothy Gauci; Morris Zwi; Richard Kirubakaran; Sasja J Håkonsen; Lise Aagaard; Erik Simonsen; Christian Gluud
Journal:  Cochrane Database Syst Rev       Date:  2018-05-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.